H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Rockwell Medical (RMTI) to $7 from $9 and keeps a Buy rating on the shares post the Q3 report. The company’s largest customer made a special premium products order, but expects future volumes to decline due to supplier diversification, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMTI: